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Abstract
The von Willebrand Factor A (vWF A) domain is one of the most widely distributed structural
modules in cell-matrix adhesive molecules such as intergrins and extracellular matrix proteins.
Mutations in the vWF A domain of matrilin-3 cause multiple epiphyseal dysplasia (MED), however
the pathological mechanism remains to be determined. Previously we showed that the vWF A
domain in matrilin-1 mediates formation of a filamentous matrix network through metal-ion
dependent adhesion sites in the domain. Here we show two new functions of the vWF A domain
in cartilage-specific matrilins (1 and 3). First, vWF A domain regulates oligomerization of matrilins.
Insertion of a vWF A domain into matrilin-3 converts the formation of a mixture of matrilin-3
tetramer, trimer, and dimer into a tetramer only, while deletion of a vWF A domain from matrilin-
1 converts the formation of the native matrilin-1 trimer into a mixture of trimer and dimer. Second,
the vWF A domain protects matrilin-1 from proteolysis. We identified a latent proteolytic site next
to the vWF A2 domain in matrilin-1, which is sensitive to the inhibitors of matrix proteases.
Deletion of the abutting vWF A domain results in degradation of matrilin-1, presumably by
exposing the adjacent proteolytic site. In addition, we also confirmed the vWF A domain is vital for
the secretion of matrilin-3. Secretion of the mutant matrilin-3 harbouring a point mutation within
the vWF A domain, as occurred in MED patients, is markedly reduced and delayed, resulting from
intracellular retention of the mutant matrilin-3. Taken together, our data suggest that different
mutations/deletions of the vWF A domain in matrilins may lead to distinct pathological mechanisms
due to the multiple functions of the vWF A domain.
Introduction
In cartilage, extracellular matrix (ECM) molecules medi-
ate cell-matrix and matrix-matrix interactions, thereby
providing tissue integrity. Matrilins (matn) are a novel
ECM protein family which consists at least of four mem-
bers [1]. All the members of matrilin family contain von
Willebrand Factor A domains (vWF A domain), EGF-like
domains, and a heptad repeat coiled-coil domain at the
carboxyl terminus, which is a nucleation site for the oli-
gomerization of the molecule [2,3]. Among the four
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members, matrilin-1 and matrilin-3 are expressed specifi-
cally in cartilage. Matrlin-1 forms a homotrimer and mat-
rilin-3 forms a mixture of homotetramer, -trimer, and -
dimer [4,5], in addition to the hetero-oligomers matn-1
and -3 form together [4,6]. It is not known how matn-1
forms a trimer only while matn-3 forms a mixture of
tetramer, trimer and dimer. The major structural differ-
ence between matn-1 and -3 is that matn-1 contains two
vWF A domains while matn-3 contains only one; the sec-
ond vWF A domain flanking the coiled coil domain is
missing from matn-3. In addition, matn-3 contains four
EGF repeats, while matn-1 contains only one EGF-like
domain. Previously we have shown that the number of
the EGF repeats does not affect the assembly of matrilins
[4]. In this study, we investigate whether the presence or
absence of the vWF A domain adjacent to the coiled-coil
is involved in modulating oligomeric formation of matri-
lins.
The vWF A domain is one of the most widely distributed
domains involved in cell adhesion and the formation of
multiprotein complexes[7]. These vWF A domain contain-
ing molecules include both subunits of the intergrin
receptor (α and β), sixteen collagens, and non-collagen-
ous ECM proteins such as matrilins. The property of the
vWF A domain in cell adhesion and protein-protein inter-
action is mediated, in many cases, by the metal-ion
dependent adhesion site (MIDAS) located within the
domain [8]. We have shown previously that the deletion
of the vWF A domain or mutations of the MIDAS motif in
MATN-1 abolish its ability to form pericellular filamen-
tous network [9]. This indicates that one of the functions
of the vWF A domain of matrilins is to act as an adhesion
site for its matrix ligands including collagens and prote-
oglycans [10,11]. However, this function may not be the
only function of the vWF A domain. This is indicated by
the recent identification of the mutations of MATN-3 in
multiple epiphyseal dysplasia (MED) patients [12].
MED is an osteochondrodysplasia primarily characterized
by delayed and irregular ossification of the epiphyses and
early-onset osteoarthritis [12]. Two different recessive
mutations in the exon encoding the vWF A domain of
MATN-3 cause the EDM5 form of MED [12]. These point
mutations result in single amino acid changes of V194D
or R121W. Subsequent genetic analysis indicates that the
R121W mutation is recurrent in multiple families with
common or different ancestries [13]. Interestingly,
although these residues are conserved in all matrilin fam-
ily members across species, they are not part of the MIDAS
motif [13]. This suggests that these residues in the vWF A
domain may play other important roles in addition to
protein-protein interactions.
To determine these unknown roles of the vWF A domain
in matrilins, we performed a series of deletions and muta-
tions of the vWF A domain in cartilage-specific MATN-1
and -3. We found several novel functions of the vWF A
domain of matrilins including regulation of protein secre-
tion, oligomeric assembly, and proteolysis by matrix pro-
teases.
Materials and methods
Cloning and Construction of Matrilin-3 cDNAs
Full-length mouse matrilin-3 cDNA was cloned by RT-
PCR from the RNA isolated from sternal cartilage of new-
born mice. Total RNA was isolated using RNeasy kit (Qia-
gen). RT-PCR of matrilin-3 mRNA was performed using
Titan one tube RT-PCR system (Boehringer Mannheim,
Indianapolis IN) according to manufacturer's instruction.
In brief, RNA (500 ng), dNTP (0.2 mM/each), DTT (5
mM), RNase inhibitor (5 unit), primers (0.4 μM/each),
reaction buffer (1×), and enzyme mix (1 μl) were added
in one tube and the volume adjusted to 50 μl. The reverse
transcription were performed at 50°C for 30 min and
then heated at 94°C for 2 min. Two step-PCR were used
in the same tube with the following condition: 94°C 30
sec, 50°C 30 sec, and 68°C 1.5 min for 10 cycles, and
then, the annealing temperature was raised to 55°C for
another 20 cycles. The nucleotide sequence of matrilin-3
cDNA was confirmed by DNA sequencing. This cDNA and
cDNAs encoding chicken matrilin-1 and -3 from previous
studies [4], were cloned into an expression vector
pcDNA3.1/V5-His (Invitrogen, Carlsbad, CA). Genetic
engineering including addition of a N-terminus FLAG tag,
addition or deletion of the vWF A domain, and exchange
of the coiled-coil domain between MATN1 and MATN3,
was performed by overlapping PCR with described primer
sets (Table 1). These modified cDNAs were cloned to
pcDNA3.1 in a similar fashion. The sequence of all the
inserts was confirmed by DNA sequencing.
Transfection of Matrilin cDNAs
cDNA constructs of matrilin-3 and -1 were transfected
into COS-7 cells (Monkey Kidney Fibroblast Cells) or
MCT cells (Immortalized Mouse Chondrocytes) [14]
using LIPOFECTAMINE (Life technology, Rockville, MD)
according to manufacturer instruction. Briefly, COS-7
cells or MCT chondrocytes were trypsinized and counted.
Each 60 mm plate were seeded with 6 × 105 cells, with
were allowed to attach overnight and reach 70% conflu-
ence in DMEM supplied with 10% FBS (Life technology).
The following day, the cells were rinsed with DMEM and
subjected to a DNA/LIPOFECTAMINE(Life technology)
mix for 5–24 hours. Five μg cDNA were used for single
transfection and 4 μg/each cDNA were used for co-trans-
fection, respectively. The DNA/LIPOFECTAMINE mixture
was aspirated and replaced with 3 ml DMEM supplied
with 1% FBS. The media from transfected cell culture wereJournal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
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collected at different time points (1, 2, 3, and 4 days) after
transfection. Cells were lysed on ice for 10 minutes in a
lysis buffer as previously described [15]. Cell lysates were
centrifuged at 4°C for 10 minutes. Supernatant of the cell
lysate as well as the conditioned medium were analyzed
using western blot. Some transfected cells were treated
with matrix protease inhibitors including EDTA and actin-
onin at indicated concentrations for 48 hours before the
conditioned medium was collected for analysis.
SDS-Polyacrylamide Gel Electrophoresis and Western Blot
Western blot analysis was performed with collected con-
ditioned medium or cell lysates from transfected cell cul-
ture. For non-reducing condition, collected samples were
mixed with standard 2× SDS gel-loading buffer[16]. For
reducing conditions, the loading buffer contains 5% b-
mercaptoethanol and 0.05 M DTT. Samples were boiled
for 10 minutes before loaded onto 10% SDS-PAGE gels,
or 4–20% gradient gels as indicated. After electrophoresis,
proteins were transferred onto Immobilon-PVDF mem-
brane (Millipore Corp., Bedford, MA) in 25 mM Tris, 192
mM glycine, and 15% methanol. The membranes were
blocked in 2% bovine serum albumin fraction V (Sigma
Co., St. Louis, MO) in PBS for 30 minutes and then
probed with antibodies. The primary antibodies used
were a monoclonal antibody against the V5 tag (diluted
1:5000) (Invitrogen), and a monoclonal antibody against
FLAG (diluted 1:1000) (Affinity BioReagents). Horserad-
ish peroxidase conjugated goat anti-mouse or goat anti-
rabbit IgG (H+L) (Bio-Rad Laboratories, Melville, NY),
diluted 1:3,000, was used as a secondary antibody. Visual-
ization of immunoreactive proteins was achieved using
the ECL Western blotting detection reagents (Amersham
Corp., Heights, IL) and exposing the membrane to Kodak
X-Omat AR film. Molecular weights of the immunoreac-
tive proteins were determined against two different sets of
protein marker ladders.
Protein Pulse-Chase
COS-1 or MCT cells were cultured in DMEM + 10% FBS in
12-well plates overnight. Matrilin-3 or MED-mutant mat-
rilin-3 cDNA was transfected into the cells using Lipo-
fectamin 2000 (Invitrogen). Three days after transfection,
cells were starved for 2 hours in 0.5 ml cysteine and
methionine free medium (Sigma), pulse-labeled in 100
μCi/ml medium of S-35 methionine (Amersham) for 1
hour, and chased in normal medium. After harvest of cul-
ture supernatants, monolayer cells were lysed in 1% NP-
40, 50 mM Tris, pH 7.4. Immunoprecipitation was carried
out by incubating culture supernatant or cell lysate with
1.5 μl anti-V5 antibody (Invitrogen) at 4°C for 2 hours,
followed by coupling to protein A/G plus agarose (Santa
Cruz) overnight at 4°C. After precipitation, the samples
were eluted by boiling after washing 3 times with 0.5%
Triton 100 in TBS. The eluted proteins were separated by
electrophoresis in a 4–15% SDS-PAGE gel, followed by
transferring to a PVDF membrane and exposed to X-ray
films.
Immunohistochemistry
After cells from Cos-1 and MCT cell lines were seeded
onto 8-well chamber slides, 1 μg wild-type matrilin-3 or
Table 1: Primers used in this study
Primers Primer Sequences (5'-->3') PCR purpose Results shown 
in Figures
1 TAA TAC GAC TCA CTA TAG GG T7, amplifying inserts from pCDNA3.1
2 AAG GAC GAT GAT GAC AAA GCT GCA AAT ACA 
TGT GCA CT
Adding a flag tag
3 TGT CAT CAT CGT CCT TAT AGT CCC CCC AGA 
CTC CAC AGC T
4 GAG GAG AGG GTT AGG GAT AGG CTT A Amplifying inserts from pCDNA3.1
5 ACT GCA AGC TGA GCA AGT CTT CTT G Adding a vWFA domain into minimatn3 (combining with the 
PCR product of primers 1 and 4)
Figure 4
6 ATCTGC GTT AGA GCC ACA ACA AGC AGT
7 ACT GCA AGC TGA GCA AGT CTT CTT G Replacing minimatn3 coiled-coil domain with that of matn1 
(combining with the PCR product of primers 1 and 4)
Figure 7
8 ATC TGC GTT AGA GCC ACA ACA AGC AGT
9 AAA GAA CAA CCT GGG TGG CAG TCA TGA Introducing R116W mutation in the vWFA domain Figure 2
10 TCA TGA CTG CCA CCC AGG TGG TTC TTT
11 GAT GAC AAA GCA CCT CCT CAG CCC AGA Adding a flag tag
12 ATC TTC CTC ACT GCA GGT CTT CCC ATC ATT
13 ACC TGC AGT GAG GAA GAT CCA TGC GAA TGT Creating Δmatn1 by deleting vWFA2 Figure 5
14 ACC TGC AGT TGC GAA TGT AAA TCT ATA GT
15 ACA TTC GCA ACT GCA GGT CTT CCC ATC AT Creating Δmatn1_del by deleting 4 amino acids from Δmatn1 Figure 6
16 ACT TGC TCA GCT TGC AGT GGT GGG TCA
17 TGT GGC TCT AAC GCA GAT TTT CAT TTG Amplifying mantn1 coiled-coil domain
18 ACT TGC TCA GCT GTC AGT GGT GGG TCA
19 TCT GGC TCT AAC GCA GAT TTT CAT TTG Amplifying mantn1 vWFA2 domain
The primers are numbered as in Figure 1.Journal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
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MED-mutant matrilin-3 cDNA was transfected into each
well using Lipofectamin 2000 (Invitrogen). Three days
after transfection, monolayer cells were fixed with 70%
ethanol, 50 mM glycine for 1 hour. Immunofluorescence
staining was performed by incubation of anti-V5 primary
antibody (Invitrogen) at 1:200 for 2 hours, followed by
incubation with donkey anti-mouse rhodamine second-
ary antibody (Jackson Laboratory) at 1:200 dilutions in
the presence of Hoechst Stain Solution (Sigma). Slides
were mounted with coverslips in Gel/Mount (Biomed).
Results
MED mutation in the vWFA domain of MATN3
To understand the structure-function relationship of carti-
lage-specific matrilins: MATN1 and 3, a series of cDNAs
containing mutations and deletions in MATN1 and 3 were
constructed (Fig. 1). We first tested whether the MED
point mutation (R116W) in mouse MATN3, which is
equivalent to the R121W mutation in MED patients,
affected synthesis and secretion of matn3 (Fig. 2A). The
cDNA harbouring the MED mutation (R116W MATN3)
was transfected into Cos cells. Both culture medium and
cell lysates from transfected cells were subject to western
blot analysis (Fig. 2B). While culture medium from
wildtype matn3 transfected cells contained both matn3
(56 KD band) and BSA (66 KD band), the medium from
R116W MATN3 transfected cells did not contain matn3.
Furthermore, excessive amount of R116W matn3 protein
was seen in the cell lysate. This suggests that the matn3
mutant protein was retained inside of the cells, which
resulted in defective secretion. To verify this hypothesis,
we determined the time course of the secretion of both
wildtype and mutant matn3 in culture medium (Fig. 2C).
At two days post-transfection, wildtype matn3 was
detected in the culture medium but matn3-mut was not.
Three days post-transfection, the mutant matn3 started to
be detected in the medium. Diminishing quantity and
speed of the secretion of mutant matn3 was seen in both
transfected Cos cells and MCT chondrocytes (Fig. 2C).
Because the amount of matn3 detected by western blot
reflected the accumulation of matn3 due to both matn3
synthesis and degradation, we then chased secretion of
radiolabelled matn3 after pulse-labelling its synthesis.
Secretion of the mutant matn3 was greatly reduced than
that of the wildtype matrilin-3 in MCT chondrocytes (Fig.
2D). In Cos cells, secretion of mutant matn3 was also sig-
nificantly reduced, and the majority of synthesized
mutant matn3 was retained intracellularly (Fig. 2E).
Immunocytochemistry of matrilin-3 indicated that
numerous vesicles that contained mutant mtn3 were
present in the cytoplasm (Fig. 3). In contrast, only few ves-
icles were present in wildtype matn3 expressing cells. The
cytoplasm of the mutant matn3 expressing cells was
greatly expanded with multiple vacuoles. Thus, a point
mutation (R116W) in the vWF A domain caused a defi-
ciency of matrilin-3 secretion, intracellular retention of
the mutant protein, and altered cytoplasm in mutant mat-
rilin-3 expressing cells.
Insertion of vWFA2 domain into MATN3
To understand whether the vWFA domain plays a role in
modulating matn3 oligomeric assembly, we inserted the
vWFA2 domain from MATN1 into MATN3, which nor-
mally does not contain the vWFA2 domain (Fig. 4A). The
secreted matrilin peptides were collected from the
medium of transfected cells, and analyzed on a western
blot. Anti-Flag was used to detect the Flag tag at the N-ter-
minus of the peptide, and anti-V5 was used to detect the
V5 tag at the C-terminus of the peptide. To simplify anal-
ysis, we used a mini-matn3, which has the same oligo-
meric properties as the full-length matn-3 [4]. Like what
we showed previously with the full-length matn3, the
mini-matn3 formed a tetramer (148 KD), a trimer (111
KD), and a dimer (74 KD) (Fig. 4B, lane 1). In contrast,
the vWFA2-inserted mini-matn3 (mini-matn3A2) formed
a 200 KD tetramer, but no trimer or dimer (Fig. 4B lane 2).
Thus the absence of vWFA2 domain from MATN3 affects
its oligomerization.
Deletion of vWFA2 domain from MATN1
To perform the converse experiment, we deleted the
vWFA2 domain from wildtype MATN1 (Fig. 5A). While
matn-1 formed a predominant trimer (200 KD) under
non-reducing conditions, Δmatn-1 formed a trimer (111
KD) and a dimer (74 KD) (Fig. 5B). Thus, the vWFA2
domain is also important for oligomerization of matn1
oligomers. This conclusion is consistent with our previous
observation [4]. Under reducing condition, matn-1 pre-
sented a 63 KD monomer only. For Δmatn-1, besides a 37
KD monomer, there was another peptide of 26 KD (Fig.
5B, Flag). This product could not be detected with the V5
antibody directed at C-terminus of coiled-coil (Fig. 5B,
V5). This suggests that this peptide is a Δmatn-1 without
the coiled-coil domain due to proteolytic cleavage.
Proteolysis of matn1
The presence of the 26 KD N-terminal peptide fragment
suggests that there is a cleavage site at the junction
between the vWFA2 domain and the coiled coil domain,
which is responsible for matn1 processing. This junction
consists of only four amino acid residues EEDP, which
precedes the cysteine residues responsible for covalently
link matrilin molecules in the coiled-coil domain (Fig.
6C, underlined residues). To test this hypothesis, these
four amino acid residues were deleted from the junction
site, and the resulting cDNA Δmatn-1Del was transfected
into COS cells (Fig 6A). Δmatn-1Del still formed trimer
and dimer under non-reducing conditions (Fig. 6B). Thus
elimination of the junction site did not affect trimer orJournal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
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dimer formation. However, deletion of the junction site
eliminated the 26 KD peptide under reducing conditions,
although the 37 KD monomer still existed (Fig. 6B). This
suggests the junction site is a proteolytic processing site of
matn-1. To further test this hypothesis, we determined
whether the presence of the inhibitors of matrix proteases
affected the proteolytic processing of matn-1. The pres-
ence of 5 mM EDTA in the medium completely inhibited
proteolytic processing of matn-1 either in the presence or
absence of serum, as did 100 μM actinonin (Fig. 6D). This
suggests that cleavage by matrix proteases is responsible
for the generation of the 26 KD fragment.
Exchange of the coiled-coil domain between MATN1 and 
MATN3
To determine whether the coiled-coil domain also played
a role in regulating matrilin assembly, we replaced the
coiled coil domain in mini-matn-3 with the coiled-coil
domain from matn-1 (Fig. 7A). Instead of a combination
of a tetramer, a trimer, and a dimer resulting from homo-
oligomerization of the native mini-matn-3 (Fig. 7B, lane
1), the chimeric mini-matn-3 with the coiled-coil from
matn-1 formed a trimer and a dimer only, but no tetramer
(Fig. 7B, lane 2). Thus, the coiled-coil domain is involved
in regulating matrilin oligomeric assembly.
Discussion
Our study suggests that the matrilin vWF A domain, a
widely distributed structural module in integrins and
ECM proteins, plays a role in regulating protein secretion,
assembly, and proteolysis, in addition to its well-docu-
mented role in cell-matrix adhesion [9]. These newly dis-
covered functions of the vWF A domain of matrilins are
discussed as follows.
Secretion
We show that a single point mutation in the vWF A
domain of mouse MATN3 (R116W), equivalent to the
MED mutation (R121W) in human MATN3, leads to a
deficiency of matrilin secretion in vitro which is consistent
with previous reports[17]. In addition to the decrease of
the amount of the mutant protein secreted into the
Construct production and primer set Figure 1
Construct production and primer set. The relative locations of the primers used to produce various MATN1 and MATN3 con-
structs are shown underneath the schematic models of matrilins. The primers are numbered as in Table 1. S: signal peptide; C-
C: coiled-coil domain.Journal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
Page 6 of 13
(page number not for citation purposes)
Secretion of matrilin-3 Figure 2
Secretion of matrilin-3. A. Schematic diagram of MATN3 constructs. 1: wildtype MATN3, and 2: R116W mutant MATN3. 
The diagram below indicates the position of the point mutation in mouse MATN3 and its homology to human MATN3; a line 
indicates identical amino acid residues between mouse and human MATN3 while double dots indicate conserved changes of 
amino acid residues. B. Western blot analysis of recombinant matn-3. Cell lysate or conditioned medium of COS cells trans-
fected with construct 1 or 2 was collected 48 hours after transfection, separated on a 10% SDS-PAGE under reducing condi-
tions, blotted to a membrane, and incubated with antiserum against the V5 tag. Bound antibodies were detected with a 
peroxidase-coupled secondary antibody and a chemiluminescence detection kit. Cross-reaction to BSA in the medium samples 
containing serum is indicated. C. Time course of matrilin-3 secretion. Cos cells or MCT chondrocytes were incubated in the 
presence of 1% or 5% serum as indicated. Conditioned medium was collected at the indicated days after transfection, and ana-
lyzed on a 10% SDS-PAGE under reducing conditions. Western blot analysis was performed with antiserum against the V5 tag 
of the recombinant matrilin-3. In both COS cells and MCT chondrocytes incubated under different concentrations of serum, 
the quantity or the speed of the secretion of R116W MATN3 was diminished in comparison to the wildtype MATN3. D. Auto-
radiograph of matrilin-3 secretion in culture medium of MCT chondrocytes. MCT cells were transfected with wildtype (WT) 
or R116W mutant (MUT) matrilin-3 cDNA. Synthesized proteins were pulse-labelled with S-35 methionine for 1 hour and 
chased for 1 hour (1 h), 4 hours (4 h), 8 hours (8 h), and 24 hours (24 h). After each chase period, conditioned medium was 
collected for immunoprecipitation with an antibody against the V5 tag of the recombinant matrilin-3. Equal protein amount was 
loaded in each lane of the SDS-PAGE gel for autoradiogram analysis. E. Autoradiograph of recombinant matrilin-3 in the cell 
lysate and conditioned medium of matrilin-3 cDNA transfected Cos cells. Cos cells were transfected with wildtype (WT) or 
R116W mutant (MUT) matrilin-3 cDNA. Synthesized proteins were pulse-labelled with S-35 methionine for 1 hour and chased 
for 1 day (1 D), or 2 days (2 D). After each chase period, conditioned medium was collected and cells were lysed for immuno-
precipitation with an antibody against the V5 tag of the recombinant matrilin-3. Equal protein amount was loaded in each lane 
of the SDS-PAGE gel for autoradiogram analysis.
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medium (Fig. 2B), the secretion time course is markedly
delayed for 24 hours (Fig. 2C, D). In the meantime, exces-
sive amount of the mutant protein is accumulated intrac-
ellularly (Fig. 2B, E). These observations indicate that
intracellular retention of the mutant protein is responsi-
ble for the deficiency of protein secretion in quantity and
speed. Consistent with this hypothesis, we observed a
great increase of intracellular vesicles that contain mutant
matrilin-3 (Fig. 3). The vWF A domain is composed of
about 200 amino acid residues arranged into multiple α-
β units, which results in a three dimensional structure of
a central β sheet core flanked by α helices [8]. Because
R121 is located in one of the β strands, despite the molec-
ular mechanism is still under investigation, it strongly
suggests that abnormal protein folding contributes to the
secretion deficiency of the mutant protein.
Although matrilin-3 is the only matrilin family member
that has been associated with chondrodysplasia so far,
more and more point mutations within the vWF A
domain of matrilin-3 have been reported to cause MED.
They include mutations A219D, I192N, T120M, and
E134K [13]. Interestingly, all of these MED-causing muta-
tions are located in the β strands in the center of the vWF
A domain, which are important for the folding of the pro-
tein structure [13]. It suggests that the secretion deficiency
due to intracellular retention of the mutant protein, as
demonstrated by this study, is a common mechanism of
matrilin-3 associated MED. Such mechanism is similar to
Immunocytochemistry analysis of matrilin-3 transfected cells Figure 3
Immunocytochemistry analysis of matrilin-3 transfected cells. Cos cells were transfected with either wildtype (WT) or R116W 
mutant (MUT) matrilin-3 cDNA. Three days post-transfection, immunocytochemistry analysis was performed with an antibody 
against the V5 tag of the recombinant matrilin-3. Matrilin-3 positive signals are indicated by rhodamine (red) fluorescence, 
while the cell nucleus is indicated by Hoechst dye (blue). Please note the expanded cytoplasm in mutant matrilin-3 transfected 
cells. Arrows indicate the presence of multiple vacuoles in those cells. Bar = 6 μm.Journal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
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Insertion of vWF A2 domain into MATN3 alters its oligomerization Figure 4
Insertion of vWF A2 domain into MATN3 alters its oligomerization. A. Schematic diagram of Construct 1: MINI-
MATN-3; and Construct 2: MINI-MATN-3 A2. B. Western blot analysis of the conditioned medium from Cos cells expressing 
(1) MINI-MATN-3, or (2) MINI-MATN-3, collected 72 hours after transfection. FLAG: analysis using the antiserum against the 
FLAG tag at the N-terminus of the recombinant matn-3. V5: analysis using the antiserum against the V5 tag at the C-terminus 
of the recombinant protein. Reducing conditions and the molecular weights of the Mini-Matn3 oligomers were indicated on the 
left, while the molecular weights of the Mini-Matn3 A2 oligomers are indicated on the right.
Deletion of vWF A2 domain from MATN1 alters its oligomerization Figure 5
Deletion of vWF A2 domain from MATN1 alters its oligomerization. A. Schematic diagram of Construct 1: MATN1; 
and Construct 2: MATN1ΔA2. B. Western blot analysis of the conditioned medium from Cos cells transfected with Construct 
1 or Construct 2, under the same experimental conditions as described in the Figure 3 legend. Reducing conditions and the 
molecular weights of the Matn1 oligomers were indicated on the left, while the molecular weights of the Matn1ΔA2 oligomers 
are indicated on the right.Journal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
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that of a point mutation of cartilage oligomeric matrix
protein (COMP), which also leads to MED or related
pseudoachondroplasia[18]. It has been demonstrated
previously that the mutant COMP is retained in the rough
endoplasmic reticulum [19]. This retention in turn results
in excessive accumulation of the proteins that are associ-
ated with COMP such as collagen type IX, whose muta-
tion also leads to similar clinical manifestation[20]. Our
observation that cells expressing mutant matrilin-3
exhibit expanded cytoplasm with multiple vacuoles,
which is similar to the phenotype of mutant COMP
expressing cells [18,20], suggests that mutated matrilin-3
or COMP may lead to common cellular phenotype. In
light of the recent discovery that COMP interacts with
matrilin-1, -3, and -4[21], our finding here lends support
to the hypothesis that mutations in any of these interact-
ing proteins including matrilin, COMP, or collagen IX,
result in a secretion defect, which manifests in common
chondrodysplasia pathological phenotypes. It should also
be noted that a portion of the mutant protein is secreted
into the medium. However, we do not know whether the
mutant protein is defective in its adhesion to matrix lig-
ands or subject to extracellular proteolysis. These possibil-
ities remain to be determined in future studies.
Assembly
The oligomeric assembly of matrilins is complex. This
complexity is two fold. First, in contrast to some ECM pro-
Deletion of the latent matrix protease site eliminates processing, but does not affect oligomerization of MATN1ΔA2 Figure 6
Deletion of the latent matrix protease site eliminates processing, but does not affect oligomerization of 
MATN1ΔA2. A. Schematic diagram of Construct 1: MATN1ΔA2; and Construct 2: MATN1ΔA2Del. B. Western blot analysis 
of conditioned medium of Cos cells transfected with Construct 1 or 2 under the same experimental conditions as described 
above. C. Proteolytic cleavage of MATN1ΔA2Del is inhibited by matrix protease inhibitors EDTA and actinonin. Cos cells 
transfected with MATN1ΔA2Del were incubated with EDTA and actinonin at indicated concentrations for 48 hours in the 
presence or absence of 1% FBS. Conditioned medium was collected for western blot analysis under reducing conditions using 
antiserum against the FLAG tag.
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tein families such as collagens that always form a trimeric
structure, different matrilin member forms different set of
oligomers. While the major oligomeric forms of matrilin-
1, -2 and -4 are trimers, matrilin-3 is a tetramer [4,22]. Sec-
ond, in addition to the major oligomeric form, each mat-
rilin has minor oligomeric forms. For example, matrilin-2
has a tetramer and a dimer in addition to a trimer, and
matrilin-3 has a trimer and a dimer in addition to a
tetramer. So far, two theories have been proposed to
explain the cause of heterogeneity of matrilin oligomers.
One is proteolytic processing, which proposes that the
heterogeneity of the matrilin derives from the proteolytic
cleavage of a single matrilin oligomer [22]. Indeed, stud-
ies using the peptide of the coiled-coil domain demon-
strate that each matrilin peptide forms a single homo-
oligomer, with matrilin-1, -2, and -4 being a trimer and
matrilin-3 being a tetramer [23,24]. Furthermore, Klatt et
al. demonstrated that proteolytic cleavage of a matrilin-4
trimer generates a dimer and a monomer [22]. However,
the proteolytic processing theory cannot explain all the
heterogeneity of matrilin oligomers. For example, it can-
not explain how a matrilin-2 trimer gives rise to a tetramer
through proteolytic cleavage.
We proposed an alternative theory that heterogeneity of
oligomeric forms of matrilins may arise from imperfect
oligomerization [4], in addition to protein processing.
The imperfect oligomerization hypothesis was based on
the fact that the amino acid sequence of the oligomeric
nucleation site coiled-coil domain, although strongly
favours one oligomeric form, has ambiguity for alternate
forms [25]. This ambiguity is modulated by the vWF A
domain next to the coiled-coil domain. Our study here
put this hypothesis to test. First, replacing the coiled-coil
domain of matrilin-3 with that of matrilin-1 changes the
matrilin-3 oligomeric forms from a combination of a
tetramer, a trimer, and a dimer into a combination of a
trimer and a dimer, reminiscent of those of matrilin-1
(Fig. 7). Thus, the coiled-coil domain primarily deter-
mines the oligomeric forms of matrilins. Second, the vWF
A domain next to the coiled-coil further modulates the
diversity of matrilin oligomeric forms. Deletion of the
vWFA2 domain from matrilin-1 converts the formation of
a predominant trimer into a mixture of trimer and dimer
(Fig. 5), while insertion of the vWFA2 domain into matri-
lin-3 converts the formation of a mixture of tetramer,
trimer, and dimer into a tetramer only (Fig. 4). The vWFA
domain may achieve this modulatory role in two ways, by
affecting either matrilin processing or assembly. The iden-
The coiled-coil domain regulates oligomerization of matrilins Figure 7
The coiled-coil domain regulates oligomerization of matrilins. A. Schematic diagram of Construct 1: MINI-MATN3; 
and Construct 2: MINI-MATN3_1CC. B. Western blot analysis of conditioned medium collected from Cos cells transfected 
with Construct 1, or 2 using antiserum against the V5 tag. Reducing conditions are indicated. Molecular weights of the MINI-
MATN3 oligomers are indicated on the left, while those of MINI-MATN3_1CC are indicated on the right.Journal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
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tification of a latent matrilin-1 cleavage site (EEDP) at the
junction of the vWFA2 domain and the coiled-coil
domain seems to suggest that different oilgomeric forms
of matrilins arise from processing at this site. However,
deletion of this cleavage site, which clearly eliminates pro-
tein processing, does not reduce the number of different
matrilin oilgomeric forms (Fig. 6B). Thus, the diversity of
the matrilin oligomeric forms cannot be attributed to pro-
tein processing alone. The vWFA2 domain, therefore,
must play a role in regulating matrilin oligomeric forma-
tion as well.
Proteolysis
In this study, we discovered a previously unsuspected
latent proteolytic site in matrilin-1 between the vWF A
domain and the coiled-coil domain. We found that,
although wildtype matrilin-1 is not cleaved, deletion of
the vWF A2 domain generates a cleaved peptide without
the coiled-coil domain. The cleavage site was predicted to
be in the junction region according to the molecular
weight of the cleaved peptide. We confirmed the location
of the cleavage site by deleting the junction region
sequence EEDP, which eliminates processing (Fig. 6B).
Based on these findings, we hypothesize that the proteo-
lytic site is normally shielded by the abutting vWF A2
domain because of the extremely short junction region
(Fig. 8). Thus the vWF A2 domain may inhibit proteolytic
processing of matrilin-1 by steric hindrance of the neigh-
bouring cleavage site. This cleavage site is sensitive to the
inhibitors of matrix proteases. Proteolytic cleavage is
inhibited by cation chelator EDTA at 5 mM (Fig. 6C). This
suggests that this matrix protease is cation dependent. The
proteolysis is completely inhibited by 100 μM actinonin,
which is known to inhibit 100% of the activity of aggre-
canses, but only 23% of the activity of matrix metallopro-
teinase (MMP) [26]. This indicates that the matrix
protease that cleaves mutated matrilin-1 is likely to be a
member of aggrecanse family. Further studies are needed
to determine the identity of this matrix protease.
Based on our current study and the studies from other lab-
oratories [22,27], we propose that the junction region
The junction region of matrilins contains potential proteolytic cleavage sites Figure 8
The junction region of matrilins contains potential proteolytic cleavage sites. Schematic diagram illustrating that the 
vWF A2 domain shields the neighbouring cleavage site by steric hindrance.
Table 2: The junction region of matrilins contains potential proteolytic cleavage sites.
Matrilin Species Amino Acid Sequence Number (a.a.)
MATN1 Human EEDP 4
Mouse EEDP 4
Chicken EEDP 4
MATN2 Human KLKKGICEALEDSDGRQDSPAGELPKTVQQPT ESEPVTINIQDLLSCSNFAVQHRYLFEEDNLL 
RSTQKLSHSTKPSGSPLEE
83
Mouse KLKEGICEALEDSGGRQDSAAWDLPQQAHQP TEPEPVTIKIKDLLSCSNFAVQHRFLFEEDN 
LSRSTQKLFHSTKSSGNPLEE
83
Chicken ELKVQICEALRNSAHQQHLSSGRLHRTNPQPSGPESTTVEITDVLACPSLAIQHKYLFEDSQSHSTRTTAKT 72
MATN3 Human ATEEARRLVSTEDA 14
Mouse DIEEARSLISIEDA 14
Chicken RATTSSLVTDEEA 13
MATN4 Human PEEGISAGTELRSP 14
Mouse PEEGIGAGTELRSP 14
Chicken PEEGRGETEIRSP 13
A pair of glutamic residues as the putative matrix cleavage site is underlined and is present in all the members of matrilin family across species with 
the only exception of chicken MATN2. a.a.: amino acid.Journal of Orthopaedic Surgery and Research 2008, 3:21 http://www.josr-online.com/content/3/1/21
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between the coiled-coil domain and its N-terminal neigh-
bouring domain contains hot spots for proteolytic cleav-
age by matrix proteases. This region varies in length,
ranging from a mere 4 amino acids in matrilin-1 to a
unique domain of 72 to 83 amino acids in matrilin-2
(Table 2). For a small junction region such as that in mat-
rilin-1 (4 amino acids), the presence of the neighbouring
vWF A2 domain shields the site from being cleaved. On
the other hand, the cleavage site in a longer junction
region such as that in mouse matrilin-4 (14 amino acids)
is not completely shielded by the neighbouring vWF A2
domain [22]. The latent matrilin-1 cleavage site contains
two glutamic acid residues. Such a pair of glutamic resi-
dues has been identified as a cleavage site in the junction
region of matrilin-4 [22], and is present in the junction
regions of matrilin-2 and -3. Thus, they are candidate sites
of matrilin proteolysis by matrix proteases.
One of the major functions of the junction region con-
taining these cleavage sites is to process matrilins and gen-
erate proteolytic fragments. The cleavage in the junction
region of matrilins separates the vWF A domain that binds
matrix ligands from the coiled-coil domain that oligomer-
izes matrilins. Such proteolytic cleavage may destabilize
or destroy matrilin filamentous network in extracellular
matrix. Our study raises a possibility that mutation/dele-
tion of the vWF A domain may change its conformation
to expose the mutant matrilin for accelerated proteolytic
degradation.
Conclusion
Different mutations/deletions of the vWF A domain in
matrilins may lead to distinct pathological mechanisms
due to the multiple functions of the vWF A domain. This
may explain how different mutations within matrilin-3
lead to a variety of cartilage diseases.
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